Incanthera plc

AQSE Growth Market -
The Company is a specialist oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company’s current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and is currently being prepared for licensing to a commercial partner within 12-18 months.

The Company originated from the Institute of Cancer Therapeutics – University of Bradford and, in addition to Sol, has acquired and developed a portfolio of specific cancer-targeting therapeutics through a pipeline agreement with the Institute of Cancer Therapeutics and other corporate acquisitions. Incanthera’s strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

Symbol Ccy Code Bid Ask Mid Previous Close Volume Last Traded
INC GBX 13 13.3 13.15 13.15 100 15.06.21

MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.

Key Information

  
Market Cap: £9.74m
ISIN:GB00BGL7YW15
Par:0.02
Inst Type:Ordinaries
Symbol:INC
MIFID Status:MTF
Tradable securities in issue:74,082,871
Sector:Pharmaceuticals & Biotechnology
Last results date:31.03.21
% price change since listing:25.24%
% daily price change:0.00%

Latest Trades

Date & Time Volume Price
15.06.21  |  12:24:5510012.988
14.06.21  |  11:43:403500012.988
08.06.21  |  12:02:142500012.98
04.06.21  |  16:42:201600013
02.06.21  |  10:38:251600013.1
01.06.21  |  16:36:504000013
01.06.21  |  16:30:05676913
01.06.21  |  11:57:1913596512
01.06.21  |  11:54:554400013
01.06.21  |  11:54:47600013

Latest Announcements

Date & Time Title
14.06.21  |  07:00:00Incanthera PLC - AGM 2021 - COVID Update
19.05.21  |  07:00:00Incanthera PLC - Notice of AGM and Posting of Annual Report
18.05.21  |  07:00:00Incanthera PLC - Final Results
13.05.21  |  07:00:00Incanthera PLC - Company Presentation Shares/AJ Bell Webinar 19 May
29.04.21  |  07:00:00Incanthera PLC - Appointment of Company Secretary
23.04.21  |  10:09:00Incanthera PLC - Holding(s) in Company
19.04.21  |  07:00:00Incanthera PLC - Directors Dealings
16.04.21  |  07:00:00Incanthera PLC - Grant of Options
12.04.21  |  12:34:00Incanthera PLC - Result of GM
01.04.21  |  07:00:00Incanthera PLC - Company Webinar Presentation

Financial Information

Click here to download a glossary of terms.

All data provided by Fregnan.

31.03.21
Enterprise Value £11.33m
EV/EBITDA (11.15)
EV/EBIT (11.15)
   
PE Ratio (12.52)
PEG 158.54%
Dividend Yield -
Free Cash Yield (6.88)%

Click here to download a glossary of terms.

All data provided by Fregnan.

31.03.19
(£'000)
31.03.20
(£'000)
31.03.21
(£'000)
Income Statement      
Revenue ---
Operating Income (EBIT) (1,848)(1,226)(1,016)
Net Income (1,988)(1,128)(905)
       
Balance Sheet      
Cash 176392957
Total Debt ---
Total Liabilities 223177165
Total Equity 1,0041,2141,691
       
Operating Margin 0.00%0.00%0.00%
EPS - Basic (4.80)p(2.27)p(1.44)p
EPS - Growth -(52.64)%(36.71)%
Dividend Per Share ---
Average Shares Outstanding 41.43m49.64m62.93m
       
ROA (152.34%)(86.17%)(55.74%)
ROCE (298.06%)(110.55%)(69.95%)
ROE (320.65%)(101.71%)(62.31%)

Click here to download a glossary of terms.

All data provided by Fregnan.

31.03.19
(£'000)
31.03.20
(£'000)
31.03.21
(£'000)
Revenue ---
Cost of Revenue 106--
Depreciation & Amortisation 133135-
Gross Profit (239)(135)-
Other Operating Expenses 1,6091,0911,016
Operating Income (EBIT) (1,848)(1,226)(1,016)
Net Interest Expense ---
Unusual Expense (incl. Exceptionals) ---
Non-Operating Expense (164)--
Profit (pre-tax) (2,012)(1,226)(1,016)
Taxation 2498111
Other Expenses and Minortity Interest ---
Net Income (1,988)(1,128)(905)

Click here to download a glossary of terms.

All data provided by Fregnan.

31.03.19
(£'000)
31.03.20
(£'000)
31.03.21
(£'000)
Cash from Operations (2,352)(518)(779)
Cash from Investing ---
Cash from Financing 2,3867341,344
Other Miscellaneous ---
Net Cash Flow 34216565

Click here to download a glossary of terms.

All data provided by Fregnan.

31.03.19
(£'000)
31.03.20
(£'000)
31.03.21
(£'000)
Current Assets 3016011,201
Non-Current Assets 926790655
Total Assets 1,2271,3911,856
Current Liabilities 223177165
Non-Current Liabilities ---
Total Liabilities 223177165
Net Assets 1,0041,2141,691
Total Equity 1,0041,2141,691

Click here to download a glossary of terms.

All data provided by Fregnan.

Address

Business Address

Incanthera plc, 76 King Street, Manchester, M2 4NH, United Kingdom.

Email: suzanne.brocks@incanthera.com

Phone: +44 (0) 161 817 5005

Registered Address

76 King Street, Manchester, M2 4NH, United Kingdom.

Contacts

Corporate Adviser

Cairn Financial Advisers LLP., Cheyne House, Crown Court, 62 - 63 Cheapside, London, United Kingdom.

Phone: +44 (0)20 7148 7900

Registrar

Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom.

Email: info@nevilleregistrars.co.uk

Phone: +44 (0) 121 585 1131